Abstract
Lung cancer is one of the most commonly diagnosed malignancies and it causes more than 1 million deaths each year worldwide. Small-cell lung cancer (SCLC) accounts for about 15 to 20% of all lung cancers and it is an extremely aggressive cancer, having a response rate of 60-80% with the standard first-line chemotherapy (CT). Topotecan is a topoisomerase I inhibitor currently approved for relapsed SCLC. The authors reviewed the clinical files of SCLCs patients (pts) of a single institution, the Portuguese Institute of Oncology – Porto Centre, in a five year period. The end-points were to evaluate response rates (RR), time to progression (TTP), overall survival (OS) and toxicity profile of topotecan as a second-line treatment of SCLC. > From January of 2002 to December of 2006, 146 pts were diagnosed with SCLC, 32 were submitted to second-line treatment and 23 with topotecan. The RR was 17.4%, median TTP and median survival after topotecan were 2.8 months and 6.3 months, respectively, and median OS was 17.5 months. The incidence of grade 3 and 4 adverse events was 16.6 and 2.6%, respectively. Topotecan showed clinical activity in our unselected daily patients with relapsed SCLC, with acceptable toxicity, in accordance with the published literature.
Keywords: Small-cell lung cancer, topotecan, topoisomerase I inhibitor
Current Drug Safety
Title: Topotecan in Second-Line Treatment of Small-Cell Lung Cancer – How it Works in Our Daily Clinical Practice?
Volume: 5 Issue: 2
Author(s): Ana Luisa Lourenco Moreira Faria, Emilio Macias Bravo, Marta Alexandra Silva Soares Rocha, Isabel Maria Azevedo Rocha, Ana Luisa Pequeno Coelho and Antonio Manuel Ferreira Araujo
Affiliation:
Keywords: Small-cell lung cancer, topotecan, topoisomerase I inhibitor
Abstract: Lung cancer is one of the most commonly diagnosed malignancies and it causes more than 1 million deaths each year worldwide. Small-cell lung cancer (SCLC) accounts for about 15 to 20% of all lung cancers and it is an extremely aggressive cancer, having a response rate of 60-80% with the standard first-line chemotherapy (CT). Topotecan is a topoisomerase I inhibitor currently approved for relapsed SCLC. The authors reviewed the clinical files of SCLCs patients (pts) of a single institution, the Portuguese Institute of Oncology – Porto Centre, in a five year period. The end-points were to evaluate response rates (RR), time to progression (TTP), overall survival (OS) and toxicity profile of topotecan as a second-line treatment of SCLC. > From January of 2002 to December of 2006, 146 pts were diagnosed with SCLC, 32 were submitted to second-line treatment and 23 with topotecan. The RR was 17.4%, median TTP and median survival after topotecan were 2.8 months and 6.3 months, respectively, and median OS was 17.5 months. The incidence of grade 3 and 4 adverse events was 16.6 and 2.6%, respectively. Topotecan showed clinical activity in our unselected daily patients with relapsed SCLC, with acceptable toxicity, in accordance with the published literature.
Export Options
About this article
Cite this article as:
Moreira Faria Luisa Lourenco Ana, Bravo Macias Emilio, Soares Rocha Alexandra Silva Marta, Azevedo Rocha Maria Isabel, Pequeno Coelho Luisa Ana and Ferreira Araujo Manuel Antonio, Topotecan in Second-Line Treatment of Small-Cell Lung Cancer – How it Works in Our Daily Clinical Practice?, Current Drug Safety 2010; 5 (2) . https://dx.doi.org/10.2174/157488610790936123
DOI https://dx.doi.org/10.2174/157488610790936123 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Daclizumab: A Potential Asthma Therapy?
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment
Current Medicinal Chemistry Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives
Current Clinical Pharmacology Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design 1,2,4-Triazine Chemistry Part III: Synthetic Strategies to Functionalized Bridgehead Nitrogen Heteroannulated 1,2,4-Triazine Systems and their Regiospecific and Pharmacological Properties
Current Organic Synthesis Hypoxic Regulation of Metastasis via Hypoxia-Inducible Factors
Current Molecular Medicine The Role of ABC and SLC Transporters in the Pharmacokinetics of Dietary and Herbal Phytochemicals and their Interactions with Xenobiotics
Current Drug Metabolism The DNA-Binding and Bioactivity of Rare Earth Metal Complexes
Mini-Reviews in Medicinal Chemistry Cysteinyl Leukotrienes (CysLTs): Role in Obesity-Induced Asthma
Current Molecular Medicine An Overview of HDAC Inhibitors and their Synthetic Routes
Current Topics in Medicinal Chemistry Palliative Radiation of Chest Tumors
Current Cancer Therapy Reviews Prediction of Cancer Rescue p53 Mutants In Silico Using Naïve Bayes Learning Methodology
Protein & Peptide Letters Expression and Function of Angiomodulating Cytokines in Rheumatoid Arthritis and Experimental Arthritis: Important Therapeutic Targets
Current Immunology Reviews (Discontinued) Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo
Current Drug Metabolism Cytoprotection and Immunomodulation in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Telomeric G-Quadruplex Architecture and Interactions with Potential Drugs
Current Pharmaceutical Design Experimental Therapy for Lung Cancer: Umbilical Cord-Derived Mesenchymal Stem Cell-Mediated Interleukin-24 Delivery
Current Cancer Drug Targets Targeted Cancer Therapeutics: Biosynthetic and Energetic Pathways Characterized by Metabolomics and the Interplay with Key Cancer Regulatory Factors
Current Pharmaceutical Design MicroRNA-16-5p Controls Development of Osteoarthritis by Targeting SMAD3 in Chondrocytes
Current Pharmaceutical Design Integrated Differential Regulatory Analysis Reveals a Novel Prognostic 36-Gene Signature for Gastric Cancer in Asian Population
Combinatorial Chemistry & High Throughput Screening